Log in to search using one of your social media accounts:

 

Algorithm increases employment opportunities for refugees
(ETH Zurich) A data-driven approach could help increase employment levels for asylum seekers in Switzerland from 15 to 26 percent. Social scientists from Switzerland and the US, in collaboration with ETH's Public Policy Group, reached this conclusion in the journal Science. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 19, 2018 Category: International Medicine & Public Health Source Type: news

Improving refugee integration through data-driven algorithmic assignment
Developed democracies are settling an increased number of refugees, many of whom face challenges integrating into host societies. We developed a flexible data-driven algorithm that assigns refugees across resettlement locations to improve integration outcomes. The algorithm uses a combination of supervised machine learning and optimal matching to discover and leverage synergies between refugee characteristics and resettlement sites. The algorithm was tested on historical registry data from two countries with different assignment regimes and refugee populations, the United States and Switzerland. Our approach led to gains o...
Source: ScienceNOW - January 18, 2018 Category: Science Authors: Bansak, K., Ferwerda, J., Hainmueller, J., Dillon, A., Hangartner, D., Lawrence, D., Weinstein, J. Tags: Sociology reports Source Type: news

Novartis's Kymriah wins speedy reviews in U.S., Europe
ZURICH (Reuters) - Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment. (Source: Reuters: Health)
Source: Reuters: Health - January 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis gets U.S. priority review for Kymriah for adults with lymphoma
ZURICH (Reuters) - Novartis has been ‍granted priority review for its cell therapy Kymriah for adults with a form of lymphoma by the U.S. Food and Drug Administration, the Swiss drugmaker said on Wednesday, as it seeks to expand use of the treatment in multiple blood cancers. (Source: Reuters: Health)
Source: Reuters: Health - January 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Joachim Flickinger appointed as the new Managing Director of S. Karger GmbH in Freiburg, Germany
Joachim Flickinger took over responsibility for S. Karger GmbH in Freiburg, Germany, as the Managing Director. Alongside his new role he will continue to serve as Director Sales & Distribution and as a member of the Management Board of S. Karger AG in Basel, Switzerland. Sibylle Gross, who had been in charge of the Freiburg office since 1993, retired at the end of 2017. As the new Managing Director in Freiburg Joachim Flickinger will be contributing his knowledge and expertise in the areas of sales and market expansion. In future, one of the goals is to better connect the Freiburg and Basel offices to leverage synergie...
Source: News from STM - January 15, 2018 Category: Databases & Libraries Authors: STM Publishing News Tags: European Featured Source Type: news

Comparative analysis of bones, mites, soil chemistry, nematodes and soil micro-eukaryotes from a suspected homicide to estimate the post-mortem interval - Szelecz I, L ösch S, Seppey CVW, Lara E, Singer D, Sorge F, Tschui J, Perotti MA, Mitchell EAD.
Criminal investigations of suspected murder cases require estimating the post-mortem interval (PMI, or time after death) which is challenging for long PMIs. Here we present the case of human remains found in a Swiss forest. We have used a multidisciplinary... (Source: SafetyLit)
Source: SafetyLit - January 15, 2018 Category: International Medicine & Public Health Tags: Jurisprudence, Laws, Legislation, Policies, Rules Source Type: news

Roche's star MS medicine Ocrevus wins EU approval
ZURICH (Reuters) - The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market. (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mobilizing agencies for incidence surveys on child maltreatment: successful participation in Switzerland and lessons learned - Jud A, Kosirnik C, Mitrovic T, Ben Salah H, Fux E, Koehler J, Portmann R, Kn üsel R.
BACKGROUND: Many countries around the world lack data on the epidemiology of agency response to child maltreatment. They therefore lack information on how many children in need get help and protection or if children stand equal chances across regions to ge... (Source: SafetyLit)
Source: SafetyLit - January 12, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Combining Cataract Surgery, Baerveldt-tube Implant Sometimes Useful for Glaucoma Combining Cataract Surgery, Baerveldt-tube Implant Sometimes Useful for Glaucoma
Cataract surgery and implantation of a Baerveldt tube (BT) for glaucoma should be done separately in most cases, but may be combined in some, research from Switzerland suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 11, 2018 Category: Surgery Tags: Ophthalmology News Source Type: news

Study identifies brain circuit controlling social behavior
(Elsevier) A new study by researchers at Roche in Basel, Switzerland has identified a key brain region of the neural circuit that controls social behavior. Increasing the activity of this region, called the habenula, led to social problems in rodents, whereas decreasing activity of the region prevented social problems. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2018 Category: International Medicine & Public Health Source Type: news

Longer placements in general practice encourage doctors to choose GP careers
The majority of medical trainees who undertake additional training placements in general practice ultimately choose a career in the profession, a Swiss study has found. (Source: GP Online News)
Source: GP Online News - January 10, 2018 Category: Primary Care Tags: Practice News Source Type: news

Invitation to Roche's Full Year Results 2017 Presentation
Roche will publish its Full Year Results for 2017 prior to the opening of the Swiss Stock Exchange on Thursday, 1 February 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - January 8, 2018 Category: Pharmaceuticals Source Type: news

Swiss biotech Oculis raises $21m for nanoparticle eye-drops
Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital. The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye. Get the full story at our sister site, Drug Delivery Business News. The post Swiss biotech Oculis raises $21m for nanoparticle eye-drops appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Funding Roundup Optical/Ophthalmic Pharmaceuticals Novartis Oculis Source Type: news

Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases
New Investors include Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners LAUSANNE, Switzerland, January 4, 2018 -- (Healthcare Sales & Marketing Network) -- Oculis (www.oculis.com), a clinical-stage biotechnology company focused on... Biopharmaceuticals, Ophthalmology, Venture Capital Oculis , Diabetic Macular Edema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 4, 2018 Category: Pharmaceuticals Source Type: news

Sociodemographic information, aversive and traumatic events, offence-related characteristics, and mental health of delinquent women in forensic-psychiatric care in Switzerland - Krammer S, Eisenbarth H, Fallegger C, Liebrenz M, Klecha D.
The present study describes a much understudied group-namely, female prisoners under forensic-psychiatric care in the German-speaking part of Switzerland-to improve understanding of their risks and their needs. Data were derived from internal databases of ... (Source: SafetyLit)
Source: SafetyLit - January 3, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Novartis breast cancer therapy gets FDA breakthrough designation
ZURICH (Reuters) - Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - January 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Prevention, diagnosis, and treatment of STIs: A PLOS medicine collection
(PLOS) This week PLOS Medicine launches the research content in our Collection on Prevention, Diagnosis, and Treatment of Sexually Transmitted Infections (STIs), advised by Guest Editors Nicola Low of the University of Bern, Switzerland and Nathalie Broutet of the World Health Organization (WHO). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 27, 2017 Category: International Medicine & Public Health Source Type: news

Medical News Today: Can playing 'shoot-em-up' style video games boost cognition?
Researchers in Switzerland have revealed that a specific type of video game may help to boost cognition. Perhaps games could be tailored for this purpose. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 26, 2017 Category: Consumer Health News Tags: Psychology / Psychiatry Source Type: news

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion
(Reuters) - Swiss drugmaker Roche will buy U.S. cancer drugmaker Ignyta Inc for $1.7 billion to broaden its oncology portfolio globally, the companies said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis combo therapy for melanoma gets FDA priority review
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review for Novartis's Tafinlar in combination with Mekinist for treating some patients with advanced melanoma, the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

British health agency backs endobronchial valves from Pulmonx, OIympus
Pulmonx and Olympus (TYO:7733) won a nod from a British health agency for the endobronchial valves they sell to treat severe emphysema. The U.K.’s National Institute for Health & Care Excellence updated its guidance for the valves, saying it considers the clinical evidence behind them sufficient to support routine use. The one-way valves, Pulmonx’s Zephyr and the Spiration device made by Olympus, are designed to partition diseased lung tissue from healthy tissue to improve respiratory efficiency. Redwood City, Calif.-based Pulmonx said the decision was based on data from a quartet of studies ...
Source: Mass Device - December 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Respiratory Olympus Pulmonx U.K. National Institute for Health & Care Excellence (NICE) Source Type: news

Roche scores cancer drug approvals in Europe and U.S.
ZURICH (Reuters) - Swiss drugmaker Roche has won fresh approvals for two cancer drugs in Europe and the United States, shoring up its position in new medicines as it braces for falling sales of older products. (Source: Reuters: Health)
Source: Reuters: Health - December 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Alecensa receives EU approval to treat ALK-positive lung cancer
ZURICH (Reuters) - The European Commission has approved Roche's Alecensa as treatment for a form of lung cancer common in patients without a significant smoking history, the Swiss drug maker said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - December 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Meet Oregon's new chief of Financial Regulation
Andrew Stolfi is currently the chief operating officer and chief counsel at the International Association of Insurance Supervisors in Basel, Switzerland. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 20, 2017 Category: Health Management Authors: Elizabeth Hayes Source Type: news

Meet Oregon's new chief of Financial Regulation
Andrew Stolfi is currently the chief operating officer and chief counsel at the International Association of Insurance Supervisors in Basel, Switzerland. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 20, 2017 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Proof-of-concept study reveals feasibility of eliminating rabies in Africa
(University of Basel) The Swiss Tropical and Public Health Institute, together with European and African collaborators, carried out a mass dog vaccination in Chad and determined its effect on human rabies exposure. The study published in Science Translational Medicine employed a bio-mathematical method for estimating the transmission dynamics of rabies. The researchers conclude that with political will and the necessary funding, elimination of rabies is possible in Africa. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 20, 2017 Category: Infectious Diseases Source Type: news

South Korea's Samsung Bioepis says FDA to review Herceptin copy
SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Wednesday the U.S. Food and Drug Administration (FDA) has accepted for review its copy of Swiss drugmaker Roche's blockbuster breast cancer drug Herceptin for potential approval. (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche touts Swiss-led R & D unit after years in Genentech's shadow
ZURICH (Reuters) - Roche is touting prospective new drugs from its long-underperforming Swiss-led research unit after years of leaning on its California-based Genentech arm to restock its medicine cabinet. (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche, Shire court fight escalates over haemophilia drug
ZURICH (Reuters) - Roche's patent dispute with London-listed Shire over the Swiss drugmaker's new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine. (Source: Reuters: Health)
Source: Reuters: Health - December 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Italy to Allow Living Wills and the Refusal of End-of-Life Care
The new law was enacted after years of debate and pushback from conservative Catholic lawmakers. (Source: NYT Health)
Source: NYT Health - December 14, 2017 Category: Consumer Health News Authors: ELISABETTA POVOLEDO Tags: Euthanasia and Assisted Suicide Italy Law and Legislation Life-Sustaining Support Systems, Withdrawal Of Suicides and Suicide Attempts Roman Catholic Church Francis Switzerland Source Type: news

Supercoiling pushes molecular handcuffs along chromatin fibers
(Swiss Institute of Bioinformatics) As it squeezes down the chromatin fiber, the cohesin protein complex extrudes a growing loop of DNA -- a bit like the quick-lacing system of trail-running shoes. But what is powering the movement of the protein? A team of SIB scientists has found that the driving force could be the supercoiling of upstream DNA. Their research, published in Nucleic Acids Research, is thereby adding a key piece to the puzzle of gene expression regulation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 14, 2017 Category: Biology Source Type: news

Exactech touts 1st Vantage total ankle mobile bearing procedure
Exactech (NSDQ:EXAC) said this week its Vantage total ankle mobile bearing system was used in its first commercial surgery. The procedure to implant the Vantage total ankle system was performed by Swiss Ortho Center Basel chair and device design member Dr. Victor Valderrabano in Switzerland, the Gainesville, Fla.-based company said. The case included both an ankle replacement and the correction of an ankle deformity through fibular lengthening and calcaneal osteotomies. “It was a momentous occasion to have performed the first Vantage Ankle mobile bearing surgery, and we were pleased with the implants’ stre...
Source: Mass Device - December 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Orthopedics Exactech Inc. Source Type: news

Mixing business with pleasure is bad for your health
A study from the University of Zurich in Switzerland showed those who bring work home with them are more likely to suffer from exhaustion and have a lower sense of well-being. (Source: the Mail online | Health)
Source: the Mail online | Health - December 13, 2017 Category: Consumer Health News Source Type: news

Novartis generics arm says may sell or end some products
ZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Senzime wins CE Mark for TetraGraph neuromoscular monitor
German patient monitor developer Senzime said today it won CE Mark approval in the European Union for its TetraGraph neuromuscular monitor. The newly cleared TetraGraph monitor is designed for use in the perioperative monitoring of physiologic data in surgical patients under general anesthesia and muscle relaxation using neuromuscular blocking drugs. The system is designed to stimulate a peripheral nerve to measure, analyze and display muscle function in surgical patients who’ve received NMBAs as part of their general anesthesia. “The CE mark is a major milestone for Senzime, we will immediately commence the ma...
Source: Mass Device - December 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: Diagnostics Regulatory/Compliance senzime Source Type: news

Don't mix business with pleasure
(Springer) In working life it's now almost expected that employees answer work-related emails after hours, or take their laptops with them on holiday. But the blurring of boundaries between work and personal life can affect people's sense of well-being and lead to exhaustion. This is according to Ariane Wepfer of the University of Zurich in Switzerland who, together with her colleagues, published a study in Springer's Journal of Business and Psychology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 12, 2017 Category: International Medicine & Public Health Source Type: news

Roche: Tecentriq cocktail slows kidney cancer progression
ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

This Nobel Laureate Is Worried U.S. Politics Could Endanger Scientific Research
(STOCKHOLM) — An American researcher who shared this year’s Nobel Prize for medicine bluntly criticized political developments at home in his address at the awards’ gala banquet Sunday night. Michael Rosbash, who was honored for his work on circadian rhythms — commonly called the body clock — expressed concern that U.S. government support such as that received by him and colleagues Jeffrey Hall and Michael Young is endangered. “We benefited from an enlightened period in the postwar United States. Our National Institutes of Health have enthusiastically and generously supported basic resea...
Source: TIME.com: Top Science and Health Stories - December 11, 2017 Category: Consumer Health News Authors: David Keyton and Jim Heintz / AP Tags: Uncategorized Budget Donald Trump Federal Budget Immigration micharl rosbash nobel prize onetime overnight politics Science United States Source Type: news

Searching for the CRISPR Swiss-army knife
(FECYT - Spanish Foundation for Science and Technology) Scientists at the University of Copenhagen, led by the Spanish Professor Guillermo Montoya, are investigating the molecular features of different molecular scissors of the CRISPR-Cas system to shed light on the so-called 'Swiss-army knives' of genome editing. Montoya's research group has visualized the atomic structures of the Cpf1 and Cas9 proteins to analyse each of their properties and peculiarities that make them ideal for different applications in gene modification. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

Searching for the CRISPR Swiss Army knife
(FECYT - Spanish Foundation for Science and Technology) Scientists at the University of Copenhagen, led by the Spanish professor Guillermo Montoya, are investigating the molecular features of different molecular scissors of the CRISPR-Cas system to shed light on the so-called 'Swiss Army knives' of genome editing. Montoya's research group has visualized the atomic structures of the Cpf1 and Cas9 proteins to analyze each of their properties and peculiarities that make them ideal for different applications in gene modification. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 11, 2017 Category: Biology Source Type: news

7 medtech stories we missed this week: Dec. 8, 2017
[Image from unsplash.com]From Minimus Spine’s European distribution deal to Stimwave receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Minimus Spine inks EU distribution deal Minimus Spine announced in a Dec. 4 press release that it has signed its first European distribution deal with Italian company Moss and has completed its first commercial order. Moss has exclusive distribution rights to distribute in Italy, Germany, Switzerland and the U.K. 2. Elanix, Dermacon sign wound management development deal Elanix Biotechnologies and Dermacon...
Source: Mass Device - December 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Diagnostics Food & Drug Administration (FDA) Hospital Care Pain Management Regulatory/Compliance Cagent Vascular CSA Medical Inc. Dermacon Elanix Life Spine Inc. MedTech Minimus Spin Source Type: news

Roche study finds cancer 'Velcro' that halts T-cell attack
ZURICH (Reuters) - Scientists at Swiss drugmaker Roche said on Friday they may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Announcement: Wyss Center workshop on lightsheet microscopy
(Wyss Center for Bio and Neuroengineering) We are pleased to announce that the first Wyss Center workshop on lightsheet microscopy will be held from 19 - 22 March 2018 at Campus Biotech in Geneva, Switzerland. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2017 Category: International Medicine & Public Health Source Type: news

Collaboration surges as businesses outsource discovery to academia
New data from the Nature Index show that as corporations have scaled back their own in-house research, there has been a surge in collaboration withacademic and government research bodies, as they look to share the burden of scientific discovery. These findings are featured in the Nature Index 2017 Science Inc. supplement, published today, which investigates corporate institutions’ changing role in science, how the academic research landscape is evolving as a result, and the costs and benefits of these shifting arrangements to high-quality research Previous research has shown that the long-term decline in corporate sc...
Source: News from STM - December 7, 2017 Category: Databases & Libraries Authors: STM Publishing News Tags: Featured World Source Type: news

Roche to seize leap-frog opportunity in lung cancer
LONDON (Reuters) - After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

We should be eating more fat and less carbs say scientists
A large study by Canadian researchers found people  consuming the most carbs died sooner and those eating higher levels of fats had a reduced mortality. Now Swiss experts also agree. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2017 Category: Consumer Health News Source Type: news

Collaboration surges as businesses outsource discovery to academia
New data from the Nature Index show that as corporations have scaled back their own in-house research, there has been a surge in collaboration withacademic and government research bodies, as they look to share the burden of scientific discovery.  These findings are featured in the Nature Index 2017 Science Inc. supplement, published today, which investigates corporate institutions’ changing role in science, how the academic research landscape is evolving as a result, and the costs and benefits of these shifting arrangements to high-quality research. Previous research has shown that the long-term decline in corpo...
Source: News from STM - December 6, 2017 Category: Databases & Libraries Authors: STM Publishing News Tags: Featured World Source Type: news

Australian watchdog takes GlaxoSmithKline, Novartis units to court
(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Twelve Countries Pledge to Protect Health Workers and Facilities in Conflict Areas
Aftermath of an attack on a health facility in Aleppo, Syria. Photo courtesy of the Syrian American Medical Society (SAMS), a member of the Safeguarding Health in Conflict Coalition.December 05, 2017IntraHealth International, as co-secretariat of theSafeguarding Health in Conflict Coalition, applauds a newdeclaration by Franceand 11 other UN member states to take concrete actions to protect health workers in conflict areas around the world.Areport by the coalition documents attacks on health workers or facilities in 23 countries in conflict or political unrest last year. Health workers were arrested, assaulted, kidnapped, ...
Source: IntraHealth International - December 5, 2017 Category: International Medicine & Public Health Authors: cbales Source Type: news

Towards a national child and adolescent health strategy in Switzerland: strengthening surveillance to improve prevention and care - Dratva J, Stronski S, Chiolero A.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - December 2, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news